Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients. The company offers enoxaparin, a low molecular weight heparin that is used as an anticoagulant for the prevention and treatment of deep vein thrombosis; naloxone for opioid overdose; Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; and lidocaine jelly, a local anesthetic product for urological procedures. It also provides lidocaine topical solution for various procedures; phytonadione injection for newborn babies; syringe products, such as morphine, atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate for emergency use in hospital settings; lorazepam injection for surgery and medical procedures; ketorolac for acute pain management; procainamide for documented ventricular arrhythmias; medroxyprogesterone acetate injectable suspension for the prevention of pregnancy. In addition, the company manufactures and distributes recombinant human and porcine insulins. Further, it develops Primatene Mist, an over-the-counter epinephrine inhalation product candidate for the temporary relief of mild symptoms of intermittent asthma. Additionally, the company has a pipeline of 20 generic and proprietary product candidates in various stages of development for various indications. Its products are used in hospital or urgent care clinical settings, and primarily contracted and distributed through group purchasing organizations and drug wholesalers. Amphastar Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AMPH
Previous Symbol
CUSIPN/A
Phone909-980-9484
Debt
Debt-to-Equity Ratio0.10
Current Ratio2.02
Quick Ratio1.34
Price-To-Earnings
Trailing P/E Ratio54.39
Forward P/E Ratio187.91
P/E Growth8.93
Sales & Book Value
Annual Sales$240.18 million
Price / Sales3.97
Cash Flow$0.7128 per share
Price / Cash29.00
Book Value$7.40 per share
Price / Book2.79
Profitability
EPS (Most Recent Fiscal Year)$0.38
Net Income$4.50 million
Net Margins-2.33%
Return on Equity2.80%
Return on Assets2.02%
Miscellaneous
Employees1,644
Outstanding Shares46,100,000
Market Cap$977.75 million
OptionableOptionable
Amphastar Pharmaceuticals (NASDAQ:AMPH) Frequently Asked Questions
What is Amphastar Pharmaceuticals' stock symbol?
Amphastar Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMPH."
How will Amphastar Pharmaceuticals' stock buyback program work?
Amphastar Pharmaceuticals announced that its Board of Directors has initiated a share repurchase plan on Thursday, August 10th 2017, which permits the company to repurchase $20,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to repurchase up to 2.8% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company's leadership believes its shares are undervalued.
How were Amphastar Pharmaceuticals' earnings last quarter?
Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) released its quarterly earnings data on Thursday, November, 8th. The company reported $0.12 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.11 by $0.01. The company earned $75.54 million during the quarter, compared to analysts' expectations of $76.84 million. Amphastar Pharmaceuticals had a positive return on equity of 2.80% and a negative net margin of 2.33%. The business's revenue was up 30.5% on a year-over-year basis. During the same quarter last year, the business earned $0.07 earnings per share. View Amphastar Pharmaceuticals' Earnings History.
When is Amphastar Pharmaceuticals' next earnings date?
What price target have analysts set for AMPH?
5 brokerages have issued 1-year price targets for Amphastar Pharmaceuticals' stock. Their forecasts range from $19.00 to $26.00. On average, they anticipate Amphastar Pharmaceuticals' stock price to reach $24.00 in the next year. This suggests a possible upside of 16.1% from the stock's current price. View Analyst Price Targets for Amphastar Pharmaceuticals.
What is the consensus analysts' recommendation for Amphastar Pharmaceuticals?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amphastar Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amphastar Pharmaceuticals.
Has Amphastar Pharmaceuticals been receiving favorable news coverage?
Media headlines about AMPH stock have trended neutral this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Amphastar Pharmaceuticals earned a news sentiment score of 0.1 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next several days.
Who are some of Amphastar Pharmaceuticals' key competitors?
Some companies that are related to Amphastar Pharmaceuticals include GW Pharmaceuticals PLC- (GWPH), Agios Pharmaceuticals (AGIO), Horizon Pharma (HZNP), Emergent Biosolutions (EBS), FibroGen (FGEN), Evotec (EVTCY), Ligand Pharmaceuticals (LGND), Array Biopharma (ARRY), Endo International (ENDP), Intercept Pharmaceuticals (ICPT), Mallinckrodt (MNK), Blueprint Medicines (BPMC), Ultragenyx Pharmaceutical (RARE), Akcea Therapeutics (AKCA) and Ascendis Pharma A/S (ASND).
Who are Amphastar Pharmaceuticals' key executives?
Amphastar Pharmaceuticals' management team includes the folowing people:
- Dr. Ziping Luo, Chairman, Chief Scientist & COO (Age 68)
- Dr. Yongfeng Zhang, CEO, Chief Science Officer & Director (Age 71)
- Mr. Jason B. Shandell, Pres & Director (Age 44)
- Mr. William J. Peters, CFO, Treasurer & Sr. VP of Fin. (Age 50)
- Mr. Rong Zhou, Exec. VP of Production Center (Age 59)
Who are Amphastar Pharmaceuticals' major shareholders?
Amphastar Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (12.94%), Dimensional Fund Advisors LP (4.13%), Teachers Advisors LLC (1.23%), Bank of New York Mellon Corp (0.91%), Rothschild & Co. Asset Management US Inc. (0.70%) and Wells Fargo & Company MN (0.52%). Company insiders that own Amphastar Pharmaceuticals stock include Diane G Gerst, Floyd F Petersen, Jack Y Zhang, Jason B Shandell, Michael A Zasloff, Richard K Prins, Rong Zhou, Stephen B Shohet, William J Peters and Yakob Liawatidewi. View Institutional Ownership Trends for Amphastar Pharmaceuticals.
Which institutional investors are selling Amphastar Pharmaceuticals stock?
AMPH stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., JPMorgan Chase & Co., Credit Suisse AG, BlueMountain Capital Management LLC, Rothschild & Co. Asset Management US Inc., TIAA CREF Investment Management LLC, Strs Ohio and Comerica Bank. Company insiders that have sold Amphastar Pharmaceuticals company stock in the last year include Diane G Gerst, Jason B Shandell, Michael A Zasloff, Richard K Prins, Rong Zhou, Stephen B Shohet, William J Peters and Yakob Liawatidewi. View Insider Buying and Selling for Amphastar Pharmaceuticals.
Which institutional investors are buying Amphastar Pharmaceuticals stock?
AMPH stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Dimensional Fund Advisors LP, Martingale Asset Management L P, Renaissance Technologies LLC, Nordea Investment Management AB, Matarin Capital Management LLC, Wells Fargo & Company MN and Bessemer Group Inc.. View Insider Buying and Selling for Amphastar Pharmaceuticals.
How do I buy shares of Amphastar Pharmaceuticals?
Shares of AMPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Amphastar Pharmaceuticals' stock price today?
One share of AMPH stock can currently be purchased for approximately $20.67.
How big of a company is Amphastar Pharmaceuticals?
Amphastar Pharmaceuticals has a market capitalization of $977.75 million and generates $240.18 million in revenue each year. The company earns $4.50 million in net income (profit) each year or $0.38 on an earnings per share basis. Amphastar Pharmaceuticals employs 1,644 workers across the globe.
What is Amphastar Pharmaceuticals' official website?
How can I contact Amphastar Pharmaceuticals?
Amphastar Pharmaceuticals' mailing address is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. The company can be reached via phone at 909-980-9484 or via email at [email protected]
MarketBeat Community Rating for Amphastar Pharmaceuticals (NASDAQ AMPH)
MarketBeat's community ratings are surveys of what our community members think about Amphastar Pharmaceuticals and other stocks. Vote "Outperform" if you believe AMPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
